Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.6 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia

May 1, 2016
Solithromycin is designated by FDA as a Qualified Infectious Disease Product FDA has granted Priority Review and Fast Track designation for solithromycin IV and capsules for the treatment of CABP…

ADMA Biologics Announces Pricing of Public Offering of Common Stock

April 28, 2016
RAMSEY, N.J., April 28, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and…

New Alliance Strengthens Alcon’s Focus on Developing Accommodating Intraocular Lenses

April 18, 2016
Fort Worth, Texas, April 18, 2016 – Alcon, the global leader in eye care and a division of Novartis, announced today that it has entered into a strategic alliance with…